

# A more intensive approach to diagnosis and management of asthma in primary care: a randomised controlled trial

<b>Submission date</b> 13/07/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 17/08/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 25/10/2022	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Dominick Shaw

**Contact details**  
17 Arleston Drive  
Wollaton  
Nottingham  
United Kingdom  
NG8 2FR

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
03/050

# Study information

## Scientific Title

A more intensive approach to diagnosis and management of asthma in primary care: a randomised controlled trial

## Study objectives

Use of exhaled nitric oxide will result in fewer asthma exacerbations.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

University Hospitals of Leicester (ref. no.: 9141) and the Leicester Primary Research Care Alliance (ref. no.: 0274).

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Other

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Asthma

## Interventions

Titrate steroid dose on basis of exhaled nitric oxide versus control group receiving treatment as per current BTS (British Thoracic Society) guidelines.

## Intervention Type

Drug

## Phase

Not Specified

## Drug/device/biological/vaccine name(s)

Nitric oxide

## Primary outcome measure

Asthma exacerbations.

**Secondary outcome measures**

Steroid dose (area under curve).

**Overall study start date**

01/01/2004

**Completion date**

01/01/2006

## Eligibility

**Key inclusion criteria**

1. Asthma
2. On treatment, providing it is a repeat prescription i.e., the patient suffers from chronic asthma
3. Aged 18-85

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Upper age limit**

85 Years

**Sex**

Both

**Target number of participants**

200

**Key exclusion criteria**

Recent exacerbation

**Date of first enrolment**

01/01/2004

**Date of final enrolment**

01/01/2006

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

17 Arleston Drive  
Nottingham  
United Kingdom  
NG8 2FR

## Sponsor information

**Organisation**

Asthma UK (UK)

**Sponsor details**

Summit House  
70 Wilson Street  
London  
United Kingdom  
EC2A 2DB

**Sponsor type**

Charity

**Website**

<http://www.asthma.org.uk/>

**ROR**

<https://ror.org/03z7xe21>

## Funder(s)

**Funder type**

Charity

**Funder Name**

Asthma UK

**Alternative Name(s)**

Asthma UK, Asthma + Lung UK

**Funding Body Type**

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

United Kingdom

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

Not provided at time of registration

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/08/2007		Yes	No